Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care ...

The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck ...

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

Proper nutrition is important for people diagnosed with cancer, both to help them feel better and to assist them in ...

A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...

A panel composed of 41 head and neck cancer experts systematically worked according to a modified Delphi process on (1) document compilation of evidence-based answers to different questions ...

Head and neck cancer arises in the mucosal epithelium, most often in the oral cavity, followed by the larynx and pharynx.

BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under ...

Neoadjuvant and adjuvant pembrolizumab added to standard care significantly improves event-free survival in HNSCC.

CEO Marc Voigt shares promising clinical trial updates across the company’s oncology and autoimmune programs.In head and neck ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...